Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Research & Development (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Research & Development for 4 consecutive years, with $14.8 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Research & Development rose 21.96% year-over-year to $14.8 million, compared with a TTM value of $51.8 million through Sep 2023, up 34.82%, and an annual FY2023 reading of $63.5 million, up 60.28% over the prior year.
  • Research & Development was $14.8 million for Q3 2023 at Terns Pharmaceuticals, up from $14.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $14.8 million in Q3 2023 and bottomed at $5.4 million in Q3 2020.
  • Average Research & Development over 4 years is $9.1 million, with a median of $8.4 million recorded in 2022.
  • The sharpest move saw Research & Development decreased 21.68% in 2021, then skyrocketed 70.01% in 2022.
  • Year by year, Research & Development stood at $7.8 million in 2020, then increased by 21.78% to $9.5 million in 2021, then grew by 12.64% to $10.7 million in 2022, then surged by 39.15% to $14.8 million in 2023.
  • Business Quant data shows Research & Development for TERN at $14.8 million in Q3 2023, $14.2 million in Q2 2023, and $10.7 million in Q4 2022.